Hardman & Co Research: Redx Pharma: Streamlined, focused and good value

Dow Jones received a payment from EQS/DGAP to publish this press release.

Hardman & Co Research 
Hardman & Co Research: Redx Pharma (REDX): Streamlined, focused and good value 
 
27-Nov-2018 / 16:05 GMT/BST 
 
*Hardman & Co: Streamlined, focused and good value* 
 
Redx Pharma (REDX) is a clinical-stage R&D company focused on drugs targeting 
oncology and fibrotic disease. 2018 was a year that reset the benchmarks - new 
management team, restructured organisation focused on two therapeutic areas, 
and a clean balance sheet with GBP6.5m cash. 2019 should be a busy year for the 
company, with several major milestones expected. RXC004, is due to re-start a 
Phase I/IIa trial for cancer with a revised formulation and dosing schedule. 
RXC006 has been nominated as the first development candidate in the 
anti-fibrotic programmes for progression to proof-of-concept trials. 
 
Please click here for the full report: 
 
https://www.hardmanandco.com/research/corporate-research/streamlined-focused-a 
nd-good-value/ [1] 
 
+------------------------+----------------+--------------------+ 
|*To contact us:*        |*Contacts:*     |                    | 
|                        |                |[e-mail] | 
|Hardman & Co            |Dr Martin Hall  |[e-mail]| 
|35 New Broad Street     |Dr Dorothea Hill|[e-mail] | 
|London                  |Dr Gregoire Pave|                    | 
|EC2M 1NH                |                |                    | 
|www.hardmanandco.com    |[phone]|                    | 
|*Follow us on Twitter*  |                |                    | 
|@HardmanandCo           |                |                    | 
+------------------------+----------------+--------------------+ 
 
*Hardman & Co Research can still be accessed for free after MiFID II. Please 
*click here [2] *to read the statement.* 
 
*About Hardman & Co:* For the past 21 years Hardman has been producing 
specialist research designed to improve investors' understanding of companies, 
sectors, industries and investment securities. Our analysts are highly 
experienced in their sectors, and have often been highly rated by professional 
investors for their knowledge. Our focus is to raise companies' profiles 
across the world with high-quality research, investor engagement programmes 
and advisory services. 
 
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative 
of Capital Markets Strategy Ltd and is authorised and regulated by the 
Financial Conduct Authority; our FCA registration number is 600843. Hardman 
Research Ltd is registered at Companies House with number 8256259. 
 
Our research is provided for the use of the professional investment community, 
market counterparties and sophisticated and high net worth investors as 
defined in the rules of the regulatory bodies. It is not intended to be made 
available to unsophisticated retail investors. Anyone who is unsure of their 
categorisation should consult their professional advisors. This research is 
neither an offer, nor a solicitation, to buy or sell any security. Please read 
the note for the full disclaimer. 
 
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
End of Announcement - EQS News Service 
 
751869 27-Nov-2018 
 
 
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=9648d28d9b984276cf38236f905ba1fc&application_id=751869&site_id=vwd&application_name=news 
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=5a632f52f80bd372265e4041a743aa1c&application_id=751869&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

November 27, 2018 11:05 ET (16:05 GMT)